Diosmetin alleviates the immunosuppressive tumor microenvironment in esophageal squamous cell carcinoma by dually inhibiting angiogenesis and promoting CD8+T cell cytotoxicity
Authors:
- Jimin ZhaoJZJimin Zhao
- Xiang LiXLXiang Li
- 4 March 2026
- journal article
- Published by Elsevier in Phytomedicine
- Vol. 154, 158036
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China (81572972)
This publication has 53 references indexed in Scilit:
- Angiogenesis and targeted therapy in the tumour microenvironment: From basic to clinical practiceClinical and Translational Medicine, 2025
- VEGF signaling: Role in angiogenesis and beyondBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2024
- SIRT6 Protects Against Lipopolysaccharide-Induced Inflammation in Human Pulmonary Lung Microvascular Endothelial CellsInflammation, 2023
- Immunoregulation mechanism of VEGF signaling pathway inhibitors and its efficacy on the kidneyThe American Journal of the Medical Sciences, 2023
- Nectins and Nectin-like molecules drive vascular development and barrier functionAngiogenesis, 2023
- Single‐Cell Transcriptomic Analysis of Primary and Metastatic Tumor Ecosystems in Esophageal Squamous Cell CarcinomaAdvanced Science, 2023
- Proinflammatory activity of VEGF-targeted treatment through reversal of tumor endothelial cell anergyAngiogenesis, 2022
- VEGF-VEGFR2 inhibitor-associated hyaline occlusive glomerular microangiopathy: a Japanese single-center experienceClinical and Experimental Nephrology, 2021
- Tumor angiogenesis: causes, consequences, challenges and opportunitiesCellular and Molecular Life Sciences, 2019
- Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy?Angiogenesis, 2017